RESEARCH LETTER

Estimated Urinary Flow Rate and Contrast-Associated Acute Kidney Injury Risk: The PRECLUDE (Prevention of Serious Adverse Events Following Angiography) Trial

To the Editor:

Acute kidney injury (AKI) is a common clinical syndrome diagnosed in >20% of hospitalizations, and the administration of iodinated contrast is a common cause.1,2 Contrast-associated AKI (CA-AKI) is marked by an abrupt decline in kidney function, typically occurring 2 to 5 days after administration of contrast, especially among those with risk factors for AKI such as older age, chronic kidney disease, cardiovascular disease, and diabetes mellitus. Identifying patients who are at increased risk for CA-AKI and instituting preventive measures is extremely important.

The mainstay of preventive strategies for CA-AKI is adequate intravascular volume expansion before radiocontrast exposure. The Prevention of Serious Adverse Events Following Angiography (PRECLUDE) trial demonstrated that CA-AKI incidence was similar irrespective of the use of normal saline solution versus sodium bicarbonate solution for preprocedure volume expansion, and irrespective of the use of N-acetylcysteine or matched placebo.3 Intravenous fluid protocols are often used in patients scheduled to undergo coronary angiography and other radiocontrast imaging studies. However, whether individual patients are sufficiently volume expanded at the time of radiocontrast exposure or whether measures of fluid administration predict risk for CA-AKI is untested.

An important correlate of fluid administration status is urinary flow rate. Its measurement before radiocontrast exposure is challenging because it typically requires collection of a timed urine specimen, and these are often impractical to obtain and frequently inaccurate.4 We recently derived a formula to estimate urinary flow rate from urinary creatinine concentrations and demonstrated that the equation estimates were highly correlated (r=0.91) to measured urinary flow rates.5 The formula to estimate urinary flow rate (eV) requires a single measurement of urinary creatinine concentration, as depicted next:

\[
eV = 9.5 + \frac{[(140 - \text{age}) \times \text{wt (kg)} \times (0.85 \text{if female}) \times 0.833]}{\text{UCr (mg/dL)}}
\]

We hypothesized that a low eV obtained just before radiocontrast exposure would identify individuals at higher risk for CA-AKI. We evaluated a subgroup of 791 PRECLUDE participants who gave a urine sample after intravenous crystalloid infusion and immediately before angiography.

We estimated urinary flow rate using the previously validated equation.5 We categorized individuals into quartiles of eV and compared demographics and clinical parameters across quartiles (Table 1). CA-AKI was defined as an increase in serum creatinine level from the baseline preangiography value of either at least 25% or at least 0.5 mg/dL at 3 to 5 days after angiography. We used logistic regression models to evaluate the association of eV with CA-AKI.

Among the 791 study participants, mean age was 70 years, 97% were men, 82% had diabetes, and mean estimated glomerular filtration rate was 48 mL/min/1.73 m² at baseline. Participants within the highest quartile of eV were more likely to be younger, to be White, and to have greater albuminuria. Sixty-six (8.3%) participants developed CA-AKI during follow-up. The mean eV in those who ultimately developed CA-AKI was 78 mL/h, whereas the corresponding eV in those who did not develop CA-AKI was 74.8 mL/h (Fig S1). When evaluated across eV quartiles, unadjusted rates of CA-AKI increased, but not linearly (Fig 1). Results were similar in models that adjusted for age, sex, race, body weight, and precontrast estimated glomerular filtration rate (Table S1).

Thus, although the simple eV equation is highly correlated with urinary flow rate, we found no evidence that its measurement based on a spot urinary creatinine level just before radiocontrast exposure was associated with CA-AKI in PRECLUDE. The reasons underlying these null findings are unclear, but several possibilities deserve consideration. First, all participants in PRECLUDE received either intravenous sodium chloride or sodium bicarbonate solution on a weight-based standardized protocol, which may have led to little heterogeneity in the volume of preprocedural intravenous fluid administered when we measured eV and when participants were given radiocontrast. Thus, the protocolized fluid administration approach may have biased toward a null result. Second, relatively few (8.3%) participants developed CA-AKI. Most participants received relatively small volumes of contrast material and only ~25% had percutaneous interventions, which are associated with higher rates of CA-AKI. Finally, because providers performing the angiography among PRECLUDE participants were able to augment the amount of intravenous fluid administered within certain boundaries, it is possible that participants deemed at higher risk for CA-AKI received higher volumes of intravenous crystalloid solution, which would have biased our results toward the null.

In conclusion, a low eV based on a spot urinary creatinine level after a preangiography intravenous fluid protocol was not associated with CA-AKI in participants undergoing radiocontrast studies in PRECLUDE. However, we believe it remains plausible that a simple equation to estimate urinary flow rate may provide utility to identify AKI risk in other settings. These findings should be reevaluated in larger study samples in the future to determine whether a simple, practical, and actionable
### Table 1. Select Demographic, Clinical, and Procedure Characteristics by eV in PRESERVE

|                      | eV Quartile 1 (<42 mL/h) | eV Quartile 2 (42-<61 mL/h) | eV Quartile 3 (61-<92 mL/h) | eV Quartile 4 (>92 mL/h) |
|----------------------|--------------------------|-----------------------------|-----------------------------|--------------------------|
| **N**                | 197                      | 197                         | 197                         | 200                      |
| **Age, y**           | 73 (8)                   | 70 (8)                      | 69 (8)                      | 68 (7)                   |
| **Female sex**       | 8 (4.1%)                 | 5 (2.5%)                    | 3 (1.5%)                    | 8 (4%)                   |
| **Race**             |                          |                             |                             |                          |
| White                | 153 (77.7%)              | 144 (73.1%)                 | 149 (75.6%)                 | 167 (83.5%)              |
| Black                | 33 (16.8%)               | 40 (20.3%)                  | 34 (17.2%)                  | 24 (12%)                 |
| Hispanic and other   | 11 (5.6%)                | 13 (6.6%)                   | 14 (7.1%)                   | 9 (4.5%)                 |
| **Weight, kg**       | 92 (18)                  | 100 (20)                    | 104 (24)                    | 108.59 (22.60)           |
| **Baseline serum creatinine, mg/dL** | 1.55 (0.38) | 1.54 (0.39) | 1.62 (0.49) | 1.59 (0.48) |
| **Baseline eGFR, mL/min/1.73 m^2** | 48 (12) | 50 (14) | 48 (14) | 48 (14) |
| **Diabetes**         | 150 (76.1%)              | 159 (80.7%)                 | 168 (85.2%)                 | 171 (85.5%)              |
| **Procedure type**   |                          |                             |                             |                          |
| Coronary             | 182 (92.4%)              | 171 (86.8%)                 | 168 (85.2%)                 | 176 (88%)                |
| Noncoronary          | 15 (7.6%)                | 25 (12.7%)                  | 28 (14.2%)                  | 24 (12%)                 |
| Missing data         | 0 (0.0%)                 | 1 (0.05%)                   | 1 (0.05%)                   | 0 (0.0)                  |
| Percutaneous intervention | 44 (22.3%) | 59 (29.9%) | 55 (27.9%) | 52 (26%) |
| **Volume of contrast material, mL** | 75 [55-125] | 102 [60.5-150] | 80 [55-130] | 85 [60-140] |
| **LVEDP, mm Hg**     | 18 (8)                   | 20 (9)                      | 21 (8)                      | 19 (8)                   |
| **Trial arm**        |                          |                             |                             |                          |
| Saline solution + placebo | 49 (24.9%) | 45 (22.8%) | 46 (23.4%) | 39 (19.5%) |
| Saline solution + NAC | 50 (25.4%)              | 49 (24.9%)                  | 54 (27.4%)                  | 51 (25.5%)               |
| Sodium bicarbonate solution + placebo | 46 (23.4%) | 53 (26.9%) | 46 (23.4%) | 62 (31%) |
| Sodium bicarbonate solution + NAC | 52 (26.4%) | 50 (25.4%) | 51 (25.9%) | 48 (24%) |

**Note:** n = 791. Values expressed as mean (standard deviation), number (percent), or median [interquartile range]. Abbreviations: eGFR, estimated glomerular filtration rate; eV, estimated urinary flow rate; LVEDP, left ventricular end-diastolic pressure; NAC, N-acetylcysteine; PRESERVE, Prevention of Serious Adverse Events Following Angiography; UACR, urinary albumin-creatinine ratio.

![Figure 1](https://example.com/image.png)

**Figure 1.** Acute kidney injury (AKI) rate by estimated urinary flow rate.
equation to assess urinary flow rate may identify those at higher risk for CA-AKI above and beyond traditional risk factors.

Alexander L. Bullen, Winn Cashion, Luke Webster, Paul M. Palevsky, Steven D. Weisbord, Joachim H. Ix

SUPPLEMENTARY MATERIAL
Supplementary File (PDF)
Figure S1: Distribution of estimated urinary flow rate (eV) by CA-AKI
Table S1: Association of precontrast estimated urinary flow rate and CA-AKI

ARTICLE INFORMATION
Authors’ Full Names and Academic Degrees: Alexander L. Bullen, MD, MAS, Winn Cashion, MD, MPH, Luke Webster, MD, Paul M. Palevsky, MD, Steven D. Weisbord, MD, and Joachim H. Ix, MD, MAS.

Authors’ Affiliations: Nephrology Section, Veterans Affairs San Diego Healthcare System, La Jolla (ALB, JHI); Division of Nephrology-Hypertension, Department of Medicine, University of California San Diego, San Diego, CA (ALB, LW, JHI); Renal Section, Veterans Affairs Pittsburgh Healthcare System (WC, PMP, SDW); Renal-Electrolyte Division, Department of Medicine, University of Pittsburgh, Pittsburgh, PA (WC, PMP, SDW); and Division of Preventive Medicine, Department of Family Medicine and Public Health, University of California San Diego, San Diego, CA (JHI).

Address for Correspondence: Joachim H. Ix, MD, MAS, Division of Nephrology-Hypertension, University of California San Diego, 3350 La Jolla Village Dr, Mail Code 9111-H, San Diego, CA 92161. E-mail: joix@ucsd.edu

Authors’ Contributions: Research idea and study design: ALB, JHI; data acquisition: SW, PP; data analysis/interpretation: ALB, WC, LW, SW, PP, JHI; statistical analysis: WC; supervision or mentorship: JHI, SW, PP. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

Support: PRESERVE was supported by the US Department of Veterans Affairs Office of Research and Development, Cooperative Studies Program, and the National Health and Medical Research Council of Australia. Dr Bullen is supported by a US Department of Veterans Affairs grant (IK2 BX004986-01A1), Ruth L. Kirschstein training grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK; T32DK104717), pilot grant from the University of Alabama at Birmingham and UC San Diego - O’Brien Center for AKI Research (P30 DK079337), and grant R01DK119528 (PI: Dr Joachim H. Ix) from the NIDDK. Dr Cashion is supported by NIDDK T32 DK061296. Dr Ix is supported by a midcareer mentoring award from the NIDDK (K24DK110427).

Financial Disclosure: The authors declare that they have no relevant financial interests.

Disclaimer: The contents do not represent the views of the US Department of Veterans Affairs or the US government.

Peer Review: Received August 7, 2020. Evaluated by 2 external peer reviewers with direct editorial input from the Statistical Editor and the Editor-in-Chief. Accepted in revised form December 27, 2020.

Publication Information: Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Published online February 27, 2021 with doi: 10.1016/j.jxme.2020.12.014

REFERENCES
1. Bartels ED, Brun GC, Gammeltoft A, Gjorup PA. Acute anuria following intravenous pyelography in a patient with myeloma-tox. Acta Med Scand. 1954;150(4):297-302.
2. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008;51(15):1419-1428.
3. Weisbord SD, Gallagher M, Jneid H, et al. Outcomes after angiography with sodium bicarbonate and acetylcysteine. N Engl J Med. 2018;378(7):603-614.
4. John KA, Cogswell ME, Campbell NR, et al. Accuracy and usefulness of select methods for assessing complete collection of 24-hour urine: a systematic review. J Clin Hypertens (Greenwich). 2016;18(5):456-467.
5. Webster L, Larive B, Gassman J, et al. A simple equation to estimate urinary flow rate using urine creatinine. Am J Nephrol. 2020;51(5):395-400.